Stock data
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS) reported revenue of US$17.44M and net income of -US$21.17M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$17.44M | US$10.54M | -US$19.89M | -US$21.17M | — |
| 2024 | US$15.03M | US$9.02M | -US$11.17M | -US$11.14M | — |
| 2023 | US$13.80M | US$8.27M | -US$17.30M | -US$13.58M | — |
| 2022 | US$16.02M | US$10.02M | -US$25.03M | -US$23.84M | — |
| 2021 | US$16.89M | US$12.60M | -US$20.38M | -US$20.29M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$5.15M | -US$5.48M | — |
| 2026-03-31 | US$5.14M | -US$7.68M | — |
| 2025-12-31 | US$3.82M | -US$6.89M | — |
| 2025-09-30 | US$6.78M | -US$5.40M | — |
| 2025-06-30 | US$3.82M | -US$5.01M | — |
| 2025-03-31 | US$3.02M | -US$3.86M | — |
| 2024-12-31 | US$3.70M | -US$2.83M | — |
| 2024-09-30 | US$3.86M | -US$2.62M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.